Sign In
Buy ABUS
$4.26
-0.220 (-4.91%)
At Close: Jun 02, 2026
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
07:15am, Tuesday, 07'th Nov 2023
Michael J. McElhaugh, Arbutus Co-founder and COO, to Serve as Interim CEO WARMINSTER, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Compa
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
07:30am, Tuesday, 24'th Oct 2023
WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensiv
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
10:36am, Tuesday, 12'th Sep 2023
Arbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies while discontinuing all coronavirus and oral RNA destabilizer programs.
3 Stocks to Buy For the COVID Resurgence
08:44am, Thursday, 07'th Sep 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting
Arbutus to Participate in Two Upcoming Investor Conferences
07:30am, Thursday, 07'th Sep 2023
WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
10:31am, Thursday, 03'rd Aug 2023
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago.
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
07:30am, Thursday, 20'th Jul 2023
WARMINSTER, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
02:01am, Wednesday, 07'th Jun 2023
WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus to Present at Jefferies Healthcare Conference
07:30am, Wednesday, 31'st May 2023
WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive
Arbutus (ABUS) Upgraded to Buy: Here's Why
01:45pm, Tuesday, 09'th May 2023
Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arbutus to Present at JMP Securities Life Sciences Conference
07:30am, Tuesday, 09'th May 2023
WARMINSTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
11:27am, Thursday, 04'th May 2023
Here is how Arbutus Biopharma (ABUS) and Hologic (HOLX) have performed compared to their sector so far this year.
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
10:41am, Thursday, 04'th May 2023
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.11 per share a year ago.
Arbutus Biopharma clinical hold slows hepatitis B momentum: broker
02:44pm, Wednesday, 26'th Apr 2023
Analysts at Baird Equity Research have awarded Arbutus Biopharma a ‘Neutral' rating after the early-stage biopharmaceutical company announced that its investigational new drug application for its n
Why Arbutus Biopharma Stock Is Sinking Today
11:50am, Tuesday, 25'th Apr 2023
The FDA has placed a clinical hold on AB-101, Arbutus' experimental chronic hepatitis B virus therapy. Arbutus had hoped to advance AB-101 into early-stage testing and report initial data on it later
